Status:
COMPLETED
A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet
Lead Sponsor:
ALK-Abelló A/S
Conditions:
House Dust Mite Allergy
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The primary aim of this trial is to evaluate the efficacy of the ALK house dust mite tablet given once daily compared to a placebo tablet in the treatment of house dut mite allergic rhinits. Addition...
Eligibility Criteria
Inclusion
- A history of house dust mite allergy
- Use of symptomatice medication for treatment of house dust mite allergy
- Positive skin prick test to mites
- Positive specific IgE
Exclusion
- History of uncontrolled asthma
- Overlapping symptomatice allergies
- Previous treatment with immunotherapy
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
992 Patients enrolled
Trial Details
Trial ID
NCT01454544
Start Date
October 1 2011
End Date
April 1 2013
Last Update
January 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Respiratory Diseases, Lapeyronie Hospital
Montpellier, Montpellier, France, 34295